ESTA Quote, Financials, Valuation and Earnings

IGC Pharma has a net margin of -50.05% compared to Establishment Labs Holdings's net margin of -711.67%. Establishment Labs Holdings's return on equity of -196.89% beat IGC Pharma's return on equity of -116.24%.

Establishment Labs Holdings has a consensus price target of $53.00, signalling upside risk potential of 44.73%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1050.19%. Given that IGC Pharma has higher upside potential than Establishment Labs Holdings, analysts believe IGC Pharma is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.503, suggesting its more volatile than the S&P 500 by 50.252%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $41.4M, which are larger than IGC Pharma quarterly revenues of $257K. Establishment Labs Holdings's net income of -$20.7M is lower than IGC Pharma's net income of -$1.8M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 6.16x versus 19.81x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -50.05% compared to Establishment Labs Holdings's net margin of -49.65%. Establishment Labs Holdings's return on equity of -196.89% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Establishment Labs Holdings has a consensus price target of $53.00, signalling upside risk potential of 44.73%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.2%. Given that NovaBay Pharmaceuticals has higher upside potential than Establishment Labs Holdings, analysts believe NovaBay Pharmaceuticals is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $41.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Establishment Labs Holdings's net income of -$20.7M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 6.16x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group has a net margin of -50.05% compared to Establishment Labs Holdings's net margin of -1.11%. Establishment Labs Holdings's return on equity of -196.89% beat PACS Group's return on equity of --.

Establishment Labs Holdings has a consensus price target of $53.00, signalling upside risk potential of 44.73%. On the other hand PACS Group has an analysts' consensus of $35.50 which suggests that it could grow by 261.51%. Given that PACS Group has higher upside potential than Establishment Labs Holdings, analysts believe PACS Group is more attractive than Establishment Labs Holdings.

Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison PACS Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. PACS Group pays out 71.23% of its earnings as a dividend. PACS Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Establishment Labs Holdings quarterly revenues are $41.4M, which are smaller than PACS Group quarterly revenues of $981.8M. Establishment Labs Holdings's net income of -$20.7M is lower than PACS Group's net income of -$10.9M. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while PACS Group's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 6.16x versus 0.43x for PACS Group. Usually stocks with elevated PS ratios are considered overvalued.

Viatris has a net margin of -50.05% compared to Establishment Labs Holdings's net margin of -93.48%. Establishment Labs Holdings's return on equity of -196.89% beat Viatris's return on equity of -20.24%.

Establishment Labs Holdings has a consensus price target of $53.00, signalling upside risk potential of 44.73%. On the other hand Viatris has an analysts' consensus of $11.6043 which suggests that it could grow by 39.98%. Given that Establishment Labs Holdings has higher upside potential than Viatris, analysts believe Establishment Labs Holdings is more attractive than Viatris.

Establishment Labs Holdings has a beta of 0.732, which suggesting that the stock is 26.804% less volatile than S&P 500. In comparison Viatris has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.265%.

Establishment Labs Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.79% to investors and pays a quarterly dividend of $0.12 per share. Establishment Labs Holdings pays -- of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

Establishment Labs Holdings quarterly revenues are $41.4M, which are smaller than Viatris quarterly revenues of $3.3B. Establishment Labs Holdings's net income of -$20.7M is higher than Viatris's net income of -$3B. Notably, Establishment Labs Holdings's price-to-earnings ratio is -- while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Establishment Labs Holdings is 6.16x versus 0.69x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.